Definium Therapeutics
Logotype for Definium Therapeutics Inc

Definium Therapeutics (DFTX) investor relations material

Definium Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Definium Therapeutics Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

DT120 clinical progress and regulatory plans

  • Proprietary ODT form of LSD; three positive pivotal readouts over the summer across GAD and MDD, with management citing the largest pivotal-study effect in each indication for a single dose.

  • Fourth pivotal study, the second in MDD, expected to read out in 2027; NDA filing targeted for H1 2027.

  • Filing routes under consideration include joint GAD/MDD submission, GAD first followed by an MDD sNDA, or staggered submissions potentially timed for a joint launch; pre-NDA meeting planned for Q4.

  • Breakthrough Therapy designation for both programs; frequent FDA dialogue and NDA compilation underway after pivotal work begun in Jan 2022.

Dose profile and care model

  • Retreatment is expected when symptoms return; the nine-month extension allowed up to four open-label doses for return of moderate-or-worse symptoms.

  • Data through six months showed ~25% with lasting benefit after one dose and ~one-third requiring a second; most patients appeared to fall in the one-to-three-dose range.

  • Trial observation averaged six hours, converging from a five-to-eight-hour range; one person was typically in the room with the patient, with a second staffer monitoring by video.

  • Most trial monitors were licensed clinical social workers; more open-label data expected in the near future.

  • Single dose is 100 mcg; management said accrued supply is more than sufficient for NDA filing needs.

Market and launch opportunity

  • Estimated U.S. population with GAD or MDD is 50m; management’s treatment funnel implies ~4m patients eligible for a step-three therapy after diagnosis, treatment and multiple drug failures.

  • SPRAVATO was cited as an analog at ~$2bn annual revenue and $30k-$70k annual pricing, with a ~$50k midpoint; it can involve up to 56 doses a year versus a few expected for DT120.

  • Management sees potential to launch DT120 for both GAD and MDD, and described treatment centers as integrating multiple interventions and adaptable to new modalities.

  • Management said Usona’s psilocybin filing would not set a negative pricing precedent, citing distinct programs and a focus on resourcing responsible delivery.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Definium Therapeutics earnings date

Logotype for Definium Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
Definium Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Definium Therapeutics earnings date

Logotype for Definium Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Mind Medicine (MindMed) Inc is a biopharmaceutical company focused on the development of psychedelic-inspired medicines and therapies for mental health and addiction conditions. The company engages in clinical research and product development targeting various psychiatric and neurological disorders. MindMed operates within the healthcare and biotechnology sectors. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.